Healthcare >> Analyst Interviews >> December 5, 2001
JEFFREY KRAWS is the Pharmaceutical Analyst and Senior Managing Director
of the Healthcare Research Group at Gruntal & Co., LLC. Mr. Kraws was
recently promoted to Director of Research for Gruntal & Co., LLC. Prior
to Gruntal & Co., LLC, Mr. Kraws was the Managing Director of the
Healthcare Research Group and the senior pharmaceutical analyst at First
Union/Everen Securities. Mr. Kraws provides research coverage on large
cap pharmaceutical, drug delivery, specialty pharmaceutical,
biopharmaceutical, and medical technology companies. Prior to First
Union/Everen Securities, Mr. Kraws was the Senior US Pharmaceutical
Analyst for the global Swedish/Swiss conglomerate Asea Brown Boveri, as
well as Managing Director and President of their US Brokerage/Investment
Banking operation, ABB Aros Securities, Inc. He has over 10 years of
overall experience and has previously been the Senior Pharmaceutical
Analyst at Nationsbanc Montgomery Securities, BT Alex. Brown, Inc., and
Buckingham Research. Mr. Kraws has been ranked numerous times as one of
the top 20 Pharmaceutical Analysts in the industry by Institutional
Investor, most recently in 1998, and was ranked among the top 10
Pharmaceutical Analysts in the industry for stock performance in 2000 as
tabulated by analyst ranking from Starmine.com. Mr. Kraws has also
worked within the pharmaceutical industry, responsible for competitive
analysis within the Treasury Group at Bristol-Myers Squibb. He holds an
MBA from Cornell University and a Bachelor of Science from the State
University of New York - Buffalo. Profile
Mr. Kraws: I'm a senior Pharmaceutical Analyst at Gruntal. I'm
responsible for the healthcare research team, as well as being the
Director of
